Pharmacy Department, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom.
Department of Women's & Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool, UK; Department of Pediatric Rheumatology, Alder Hey Children's NHS Foundation Trust Hospital, Liverpool, UK.
Clin Immunol. 2020 Jul;216:108447. doi: 10.1016/j.clim.2020.108447. Epub 2020 May 1.
Biosimilars are biologic medications that are slightly altered versions of already approved biologic disease modifying anti-rheumatic drugs (bDMARDs). They can be manufactured after the original product's patent protection expires. The advent of biosimilar use in pediatric rheumatology started with the biosimilar to infliximab in 2013. Since then, more biosimilars have been made available including etanercept, rituximab and adalimumab. This manuscript briefly reviews the history of biosimilar introduction to treatment and suggests strategies for the adoption of biosimilar drugs in services specialized in Pediatric Rheumatology, including potential barriers and solutions to their implementation into practice. The review covers general aspects relevant to all biosimilar drugs and specific examples covering individual drugs based on the experience of a large tertiary pediatric rheumatology service in the Northwest of England.
生物类似药是指已批准的生物制剂疾病修正抗风湿药物（bDMARDs）的稍作改变的版本。它们可以在原始产品的专利保护期过期后制造。生物类似药在儿科风湿病学中的应用始于 2013 年的类克生物类似药。自那时以来，已经有更多的生物类似药问世，包括依那西普、利妥昔单抗和阿达木单抗。本文简要回顾了生物类似药引入治疗的历史，并为儿科风湿病学专业服务机构采用生物类似药提出了策略，包括将其应用于实践中的潜在障碍和解决方案。该综述涵盖了与所有生物类似药相关的一般方面，以及基于英格兰西北部一家大型三级儿科风湿病学服务机构经验的个别药物的具体示例。
